Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: Am J Med. 2012 May 3;125(7):709–716. doi: 10.1016/j.amjmed.2011.12.004

Table 4.

Characteristics of Prophylaxis in Patients with Hospitalization or Major Surgery Within 3 Months of Subsequently Developing Venous Thromboembolism According to History of Diabetes*

Diabetes (n = 476) No Diabetes (n = 2012) P Value
Receiving any prophylaxis, n (%) 253 (60.4) 774 (46.6) <.001
Pneumatic compression devices, n (%) 134 (32.0) 430 (25.9) .01
Subcutaneous unfractionated heparin, n (%) 129 (30.8) 325 (19.6) <.001
Low-molecular-weight heparin, n (%) 47 (11.2) 141 (8.5) .09
Intravenous unfractionated heparin, n (%) 41 (9.8) 87 (5.2) .001
Warfarin, n (%) 24 (5.7) 75 (4.5) .31
*

Patients could have received >1 prophylactic modality.